➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
Merck
McKinsey
McKesson

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Avid Radiopharms Inc Company Profile


Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for AVID RADIOPHARMS INC, and when can generic versions of AVID RADIOPHARMS INC drugs launch?

AVID RADIOPHARMS INC has two approved drugs.

There are three US patents protecting AVID RADIOPHARMS INC drugs.

There are fifty-eight patent family members on AVID RADIOPHARMS INC drugs in thirty-three countries and sixteen supplementary protection certificates in sixteen countries.

Summary for Avid Radiopharms Inc
International Patents:58
US Patents:3
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Avid Radiopharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN No No 7,687,052 ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-003 Apr 6, 2012 RX Yes Yes 8,506,929 ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-002 May 28, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-003 Apr 6, 2012 RX Yes Yes 7,687,052 ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-002 May 28, 2020 RX Yes Yes 8,932,557 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-002 Apr 6, 2012 RX Yes Yes 8,506,929 ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-001 May 28, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Avid Radiopharms Inc Drugs

Country Patent Number Estimated Expiration
Japan 2009532349 ⤷  Free Forever Trial
European Patent Office 2363392 ⤷  Free Forever Trial
Canada 2715390 ⤷  Free Forever Trial
Hungary S1300028 ⤷  Free Forever Trial
Guatemala 200800201 ⤷  Free Forever Trial
Australia 2012381042 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2013176698 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Avid Radiopharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1999109 122013000051 Germany ⤷  Free Forever Trial PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 481 Finland ⤷  Free Forever Trial
1999109 CA 2013 00035 Denmark ⤷  Free Forever Trial
1999109 C20130016 00076 Estonia ⤷  Free Forever Trial PRODUCT NAME: FLORBETAPIIR (18F);REG NO/DATE: K(2013)137 (LOPLIK) 14.01.2013
1999109 34/2013 Austria ⤷  Free Forever Trial PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 13C0034 France ⤷  Free Forever Trial PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 C01999109/01 Switzerland ⤷  Free Forever Trial PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: SWISSMEDIC 62897 09.01.2014
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
Moodys
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.